2 surging growth stocks set to beat the FTSE 100

These two shares appear to be on the up and capable of outperforming the FTSE 100 (INDEXFTSE:UKX).

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

sdf

Buying shares which have posted large gains can be a sound strategy. While it can mean a lack of potential upside due to a narrow margin of safety now being in existence, there is no guarantee that a rising share price will eventually fall. In some cases, a higher share price can indicate improving financial performance and the start of a new strategy bearing fruit. As such, it can be an opportune time to buy. With that in mind, here are two shares which have made gains but could still be worth buying.

Improving performance

Reporting on Friday was specialist producer of manual and automated diagnostic testing kits, Immunodiagnostic Systems (LSE: IDH). Its shares jumped by almost 4% following its trading update for the most recent financial year. This takes their gain for the 2017 calendar year to 47%.

The company’s automated business delivered revenues which were around 3% higher than in the prior year at constant exchange rates. It also launched four new CLIA automated assays, which brought the total assay menu with a CE-mark up to 19 assays. This represents expansion of the assay menu of 25% during the year. This and developments made elsewhere in its automated division show it is making progress with its roadmaps for R&D, sales and marketing.

Passive income stocks: our picks

Do you like the idea of dividend income?

The prospect of investing in a company just once, then sitting back and watching as it potentially pays a dividend out over and over?

If you’re excited by the thought of regular passive income payments, as well as the potential for significant growth on your initial investment…

Then we think you’ll want to see this report inside Motley Fool Share Advisor — ‘5 Essential Stocks For Passive Income Seekers’.

What’s more, today we’re giving away one of these stock picks, absolutely free!

Get your free passive income stock pick

In the company’s manual business, it was able to slow the downward trend. Revenues declined by 11% versus the prior year, but a focus on building the sales process and distribution channels could lead to an end to the decline in revenue at constant exchange rates.

With a sound strategy and performance which could prove to be better than anticipated, Immunodiagnostic Systems could record further share price gains. Revenue growth of 4% indicates that its shares could be a sound buy at the present time.

Growth potential

Also offering potential upside within the healthcare sector is Shire (LSE: SHP). Its combination with Baxalta has the potential to create a dominant pharmaceutical company with a pipeline of new treatments which could positively catalyse earnings growth in the long run. Furthermore, the synergies from the deal may push earnings higher and contribute to a higher valuation for the business over the medium term.

With Shire forecast to deliver a rise in its bottom line of 15% next year, the progress of the combined entity is set to be encouraging. However, many investors are somewhat unsure as to how compatible the two businesses will be, and there are doubts surrounding the level of synergies which may be recorded. As a result, the company’s shares trade on a price-to-earnings growth (PEG) ratio of only 0.7. This indicates that they offer a wide margin of safety and their upside potential could be significant.

Certainly, there are risks in the combination of any two companies. But with a strong pipeline and a low valuation, Shire looks set to deliver robust share price performance after its 115% gain in the last five years.


Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Abstract bull climbing indicators on stock chart
Investing Articles

Could the Chancellor’s Leeds Reforms trigger a bull market for UK stocks?

More competitive lending and greater interest in shares could help kick start growth for UK businesses. But could it also…

Read more »

Concept of two young professional men looking at a screen in a technological data centre
Investing Articles

I think this AI stock could double before Palantir

Palantir stock is up almost 100% this year. As a result, it now sports a market cap of $350bn meaning…

Read more »

Elevated view over city of London skyline
Investing Articles

As the FTSE 100 hits an all-time high, is it time to reconsider the S&P 500?

Christopher Ruane explains why a surging FTSE 100 has not yet made him focus more on the potential of S&P…

Read more »

GSK scientist holding lab syringe
Investing Articles

The FTSE 100 sits at a record high. But some stocks still look dirt cheap!

The usually sluggish FTSE 100 is having a surprisingly good year. But our writer feels there are still potential bargains…

Read more »

Close-up of British bank notes
Investing Articles

With a £20k Stocks and Shares ISA, here are 3 ways an investor could target a £2k annual passive income

Our writer thinks there is more than one way to try and skin a cat when it comes to earning…

Read more »

Businessman using pen drawing line for increasing arrow from 2024 to 2025
Investing Articles

Up 350% in 3 years but my favourite FTSE growth share is still on a low P/E of just 10!

Harvey Jones can't tear his eyes away from this former penny stock turned growth share superpower. But can it carry…

Read more »

Santa Clara offices of NVIDIA
Investing Articles

Up 83% in months, could Micron stock be the next Nvidia?

Chipmaker Micron Technology's stock price has surged by over 80% in just a few months. Could this be a possible…

Read more »

Tesla car at super charger station
US Stock

£1k invested in Tesla stock at the start of the year is currently worth…

Jon Smith reveals the performance of Tesla stock in 2025 and explains why he doesn't believe the move lower is…

Read more »